Review your GLP-1 provider's public record before you enroll
GLP-1 medications are prescription drugs with real side effects and a complex regulatory landscape.
Our warning tracker currently documents 9 sourced FDA letters dated across 2025 and 2026. It is a curated subset, not a count of every agency action.
Before starting treatment:
- •Review warning-letter and pharmacy-transparency records
- •Understand side effects
- •Know your rights
Independent safety resources. No provider pays for placement in our safety assessments.
Side Effects Guide (cross-drug)
Comprehensive breakdown of GLP-1 side effects with exact percentages from FDA prescribing information. Covers nausea, GI issues, rare complications, and how to manage them.
Wegovy side effects deep dive
Per-drug guide: rates from the FDA-approved Wegovy label, week-by-week timeline, management protocols for nausea/diarrhea/constipation, red-flag symptoms, and the boxed warning explained.
Zepbound side effects deep dive
Per-drug guide for tirzepatide: rates from the FDA-approved Zepbound label, the 24-week dose-escalation timeline, management protocols including hair shedding (2× Wegovy's rate), and the boxed warning.
Ozempic side effects deep dive
Per-drug guide for the FDA-approved diabetes doses (0.5mg / 1mg / 2mg). Includes the Ozempic-specific diabetic-retinopathy warning, hypoglycemia management when combined with insulin or sulfonylureas, and the boxed warning.
Foundayo side effects deep dive
Per-drug guide for orforglipron, Eli Lilly's first oral GLP-1, FDA-approved April 2026. No fasting required. Trial data from ATTAIN-1, $149/mo self-pay, 12.4% weight loss profile.
Mounjaro side effects deep dive
Per-drug guide for tirzepatide at the diabetes indication (5mg / 10mg / 15mg). Same molecule as Zepbound but FDA-approved for T2DM. Includes diabetic-retinopathy warning, hypoglycemia management.
Rybelsus side effects deep dive
Per-drug guide for oral semaglutide (7mg / 14mg). FDA-approved for type 2 diabetes. Covers the unique fasting protocol (4oz water, 30min fast, non-negotiable for absorption), management protocols, and red flags.
FDA Warning Letters & Alerts
Review 9 sourced FDA warning-letter records involving compounded GLP-1 marketing or sales. This curated tracker links every row to fda.gov and is not exhaustive.
Warning & Transparency Checker
Review warning-letter, pharmacy-disclosure, licensing-status, and public-record fields for 36 tracked records. Unknown fields stay Unknown; the tool does not certify safety or compliance.
GLP-1 Lawsuit Tracker
Monitor active litigation against GLP-1 manufacturers and providers. Class actions, individual claims, and regulatory enforcement updates.
Three things to do before you start
Investigate Your Provider
Use our Warning & Transparency Checker to review sourced FDA letters and claim-level pharmacy details. Unknown means no supported finding in this dataset. Verify the current pharmacy and prescriber directly before enrolling.
Start Low, Go Slow
Follow the prescribed titration schedule. Rushing to higher doses increases GI side effects. Use our dosing timeline tool.
What the doctors say about GLP-1 safety
Verbatim, independently sourced statements from named physicians and medical bodies, real clinicians quoted with their sources, not a single paid reviewer. General clinical context, not an endorsement of any provider.
“Americans should be confident that the prescription drugs they take are safe. By strengthening oversight of imported APIs and cracking down on illegal drugs entering the U.S., we are taking aggressive action to protect consumers from poor-quality or dangerous GLP-1 drugs.”
“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs, but compounders should not try to compound drugs in a way that circumvents FDA's approval process.”
“We do not recommend the use of these alternatives. If you use these compounded alternatives, you may not be getting what you hoped for. You may also get something you did not want (other active substances have been found in some compounded versions).”
“Anyone who has an active contraindication for the medication, where they have had an issue, for example, medullary thyroid cancer. If they are actively in a pancreatitis flare, obviously, you wouldn't apply this medication. It's, frankly, contraindicated in those situations.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.